Cell Therapy for ALS
Amyotrophic Lateral Sclerosis
UnknownActive
Key Facts
About INCELL
INCELL operates as a hybrid products manufacturer and contract development and manufacturing organization (CDMO) in the regenerative medicine space. The company leverages its GMP capabilities to support both its own therapeutic programs and external clients, with a focus on cell culture media, transport solutions, and proprietary cell lines. Through a strategic alliance with 4RMED LLC, INCELL manages clinical development for programs targeting conditions like ALS, pneumonia, and pediatric necrotizing enterocolitis. Its business model integrates product sales, contract services, and internal therapeutic development.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| ALS Research | GliaPharm | Research |
| ALS Disease Model Service | NeuroProof | Pre-clinical |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| ALS Program | Biorchestra | Preclinical |
| Program(s) for ALS | AviadoBio | Pre-clinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ILB® for ALS | TikoMed | Phase 2 |
| ALS Patient-Led Research Initiative | BGI | Research |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |